Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

273 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. Among authors: fogel r. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
Addressing unmet needs in the treatment of COPD.
Patalano F, Banerji D, D'Andrea P, Fogel R, Altman P, Colthorpe P. Patalano F, et al. Among authors: fogel r. Eur Respir Rev. 2014 Sep;23(133):333-44. doi: 10.1183/09059180.00004014. Eur Respir Rev. 2014. PMID: 25176969 Free PMC article. Review.
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.
Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D. Wedzicha JA, et al. Among authors: fogel r. Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:339-349. doi: 10.2147/COPD.S125058. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28176893 Free PMC article. Clinical Trial.
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.
Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R. Anzueto AR, et al. Among authors: fogel r. Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28496316 Free PMC article.
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Banerji D, Fogel R, Patalano F. Banerji D, et al. Among authors: fogel r. Drug Discov Today. 2018 Jan;23(1):196-203. doi: 10.1016/j.drudis.2017.10.015. Epub 2017 Oct 24. Drug Discov Today. 2018. PMID: 29079130 Review.
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.
Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA. Vogelmeier CF, et al. Among authors: fogel r. Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29692607 Free PMC article. Clinical Trial.
273 results